News

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema\n

04 October 2024

a doctor is about to inject medicine into a patient's upper arm

UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers

04 October 2024

A syringe is being filled from a vial in front of an HIV graphic

Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lena\n

20 September 2024

A nurse preps a patient arm for an injection

GSK present data at ERS for depemokimab an asthma medication that last 6 months.

13 September 2024

First Patients Dosed in Debiopharm's Phase III Trial of a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

13 September 2024

Innovative semaglutide hydrogel could reduce diabetes shots to once a month\n

13 September 2024

Two people stand back to back lifting their sleeves to show plasters covering their recent injections

Nanoform and Celanese expand collaboration into long-acting biologics delivery through small implants

06 September 2024

Peptron to boost long-acting drug production 10-fold with new factory, investing ₩65 billion.

23 August 2024

Persist AI and Nivagen to Collaborate on AI-Driven Manufacturing Process for Long-Acting Injectable

16 August 2024

A person is sat holding their painful knee

Concentric Analgesics Announces Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids in Two Surgical Procedures

09 August 2024

News

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema\n

04 October 2024

UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers

04 October 2024

Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lena\n

20 September 2024

GSK present data at ERS for depemokimab an asthma medication that last 6 months.

13 September 2024

First Patients Dosed in Debiopharm's Phase III Trial of a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

13 September 2024

Innovative semaglutide hydrogel could reduce diabetes shots to once a month\n

13 September 2024

Nanoform and Celanese expand collaboration into long-acting biologics delivery through small implants

06 September 2024

Older Stories

Why choose Liverpool?
It’s an important question. And there are thousands of answers.

Study with Liverpool

Find a course

Search courses

Select type

Our courses

Research with real world impact

Our research

Research

Postgraduate Research

Research and business collaboration

Advancing knowledge to transform lives

About us

Our story

Key information

Our locations

Search

Find a course

Select type

News

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema\n

UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers

Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lena\n

GSK present data at ERS for depemokimab an asthma medication that last 6 months.

First Patients Dosed in Debiopharm's Phase III Trial of a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

Innovative semaglutide hydrogel could reduce diabetes shots to once a month\n

Nanoform and Celanese expand collaboration into long-acting biologics delivery through small implants

Peptron to boost long-acting drug production 10-fold with new factory, investing ₩65 billion.

Persist AI and Nivagen to Collaborate on AI-Driven Manufacturing Process for Long-Acting Injectable

Concentric Analgesics Announces Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids in Two Surgical Procedures

News

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema\n

UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers

Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lena\n

GSK present data at ERS for depemokimab an asthma medication that last 6 months.

First Patients Dosed in Debiopharm's Phase III Trial of a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

Innovative semaglutide hydrogel could reduce diabetes shots to once a month\n

Nanoform and Celanese expand collaboration into long-acting biologics delivery through small implants